Aryl-fused spirocyclic compounds
View Patent ↗The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
1. A compound represented by the following structural formula:
wherein X is
A, B, D, E, G, J, K, M and P are independently selected from CR 1 2 , NR 1a , C(O) and O; R is NH 2 or OH;
is phenyl or pyridyl;
is phenyl;
each R 1 is independently
1) hydrogen,
2) C 1 -C 6 alkyl,
3) (CR 6 2 ) n R 10 ,
4) (CR 6 2 ) n C(O)R 4 ,
5) (CR 6 2 ) n C(O)OR 4 ,
6) (CR 6 2 ) n C(O)NR 5 2 ,
7) (CR 6 2 ) n S(O) 2 R 4 ,
8) (CR 6 2 ) n OR 4 ,
9) (CR 6 2 ) n NR 5 (SO 2 )R 4 ,
10) (CR 6 2 ) n NR 5 2 ,
11) (CR 6 2 ) n NR 5 C(O)OR 4 ,
12) halo, or
13) aryl;
each R 1a is independently
1) hydrogen,
2) C 1 -C 6 alkyl,
3) (CR 6 2 ) n R 10 ,
4) (CR 6 2 ) n C(O)R 4 ,
5) (CR 6 2 ) n C(O)OR 4 ,
6) (CR 6 2 ) n C(O)NR 5 2 , or
7) (CR 6 2 ) n S(O) 2 R 4 ;
L 1 is a bond
R 3 is
hydrogen,
unsubstituted or substituted aryl,
unsubstituted or substituted heteroaryl;
each R 4 is independently
1) H,
2) C 1 -C 6 alkyl,
3) aryl, or
4) heterocyclyl,
wherein alkyl, aryl or heterocyclyl is optionally substituted with C 1 -C 6 alkyl;
each R 5 is independently
1) hydrogen,
2) C 1 -C 6 alkyl, or
3) aryl,
which may be optionally substituted with 1 to 3 substituents selected from C 1 -C 6 alkyl, aryl, heteroaryl or halo;
each R 6 is independently
1) hydrogen,
2) C 1 -C 6 alkyl,
3) aryl,
4) OR 11 ,
5) halo, or
6) NR 11 ;
wherein the alkyl or aryl may be optionally substituted with 1 to 3 substituents selected from the group consisting of C 1 -C 6 alkyl, aryl, heteroaryl and halo;
each R 10 is independently
1) aryl, and
2) heterocyclyl,
which may be optionally substituted;
each R 11 is independently hydrogen, C 1 -C 6 alkyl, or aryl, wherein said alkyl and aryl groups are optionally substituted;
n is independently selected from 0, 1, 2, 3 and 4;
q is 1;
or a stereoisomer or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 wherein R is NH 2 , or a stereoisomer or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 wherein:
is pyridinyl;
is phenyl;
or a stereoisomer or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 selected from
N-(2-aminophenyl)-6-(1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl)nicotinamide;
6-(1-acetyl-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl)-N-(2-aminophenyl)nicotinamide;
6-(1-acetyl-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl)-N42-amino-5-(2-thienyl)phenyl]nicotinamide;
6-(1-acetyl-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl)-N-[2-amino-5-(3-thienyl)phenyl]nicotinamide;
N-(2-aminophenyl)-6-{1-[(4-methylphenyl)sulfonyl]-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl]nicotinamide;
N-(4-aminobiphenyl-3-yl)-6-(2,3-dihydro-1H,1′H-spiro[isoquinoline-4,4′-piperidin]-1′-yl)nicotinamide;
N-(2-aminophenyl)-6-(1′H-spiro[indeno[2,1-b]pyridine-9,4′-piperidin]-1′-yl)nicotinamide;
N-(2-aminophenyl)-6-(1,3-diethyl-4,5-dihydro-1H,1′H-spiro[cyclopenta[c]pyrazole-6,4′-piperidin]-1′-yl)nicotinamide;
N-(2-aminophenyl)-6-(3-oxo-2,3-dihydro-1′H-spiro[isoindole-1,4′-piperidin]-1′-yl)nicotinamide;
(3R)-1′-(5-{[(2-aminophenyl)amino]carbonyl}pyridin-2-yl)-N-methyl-2,3-dihydrospiro[indene-1,4′-piperidine]-3-carboxamide;
N-[2-amino-5-(3-thienyl)phenyl]-6-(4-oxo-3,4-dihydro-1′H-spiro[chromene-2,4′-piperidin]-1′-yl)nicotinamide;
N-(4-aminobiphenyl-3-yl)-6-(1-oxo-1,4-dihydro-1′H-spiro[isochromene-3,4′-piperidin]-1′-yl)nicotinamide;
ethyl [1′-(5-{[(4-aminobiphenyl-3-yl)amino]carbonyl}pyridin-2-yl)-2,3-dihydrospiro[indene-1,4′-piperidin]-3-yl]carbamate;
N-4-aminobiphenyl-3-yl)-6-(6-methoxy-1-oxo-4-phenyl-1,4-dihydro-1H′-spiro[isochromene-3,4′-piperidin]-1′-yl)nicotinamide;
N-(2-aminophenyl)-6-(1-methyl-2-oxo-5-phenyl-1,2-dihydro-1′H-spiro[1,4-benzodiazepine-3,4′-piperidin]-1′-yl)nicotinamide;
N-(2-aminophenyl)-6-(1-isopropyl-6-methoxy-5-methyl-2-oxo-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl)nicotinamide;
N-(2-aminophenyl)-6-[5-(benzylamino)-1-isopropyl-2-oxo-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl]nicotinamide;
N-[2-amino-5-(2-thienyl)phenyl]-6-(1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl)nicotinamide;
N-[2-amino-5-(2-thienyl)phenyl]-6-(l′H-spiro[1-benzofuran-3,4′-piperidin]-1′-yl)nicotinamide;
N-[2-amino-5-(2-thienyl)phenyl]-6-[1-(methylsulfonyl)-1,2-dihydro-1′H-spiro[indole-3,4′-piperidin]-1′-yl]nicotinamide;
tert-butyl l′-(5-{[(2-aminophenyl)amino]carbonyl}pyridin-2-yl)-1H-spiro[isoquinoline-4,4′-piperidine]-2(3H)-carboxylate;
N-(2-aminophenyl)-6-(2,3-dihydro-1H,1′H-spiro[isoquinoline-4,4′-piperidin]-1′-yl)nicotinamide;
N-(4-aminobiphenyl-3-yl)-4-(1H-spiro[isoquinoline-4,4′-piperidin]-2(3H)-ylmethyl)benzamide;
N-(4-aminobiphenyl-3-yl)-4-(2,3-dihydro-1H,1′H-spiro[isoquinoline-4,4′-piperidin]-1′-ylcarbonyl)benzamide;
N-(4-{[(4-aminobiphenyl-3-yl)amino]carbonyl}phenyl)-2,3-dihydro-1H,1′H-spiro[isoquinoline-4,4′-piperidine]-1′-carboxamide;
or a stereoisomer or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1 , and a pharmaceutically acceptable carrier.
6. A method for the treatment of cervical cancer or colon carcinoma in a mammal comprising the step of administering a therapeutically effective amount of the compound of claim 1 to the mammal.